The purpose of this study is to determine if intravenous immunoglobulin (IVIG) can prevent
bacterial infections in lung transplant patients with low serum levels of immunoglobulin.
An increased risk of infection despite intensive antimicrobial prophylaxis is a
well-recognized complication of lung transplantation. Recent evidence suggests that
immunosuppressive therapy after solid organ transplantation may lead to humoral
immunodeficiency due to hypogammaglobulinemia (HGG). In lung transplant recipients with HGG,
IVIG therapy offers the potential to significantly decrease the incidence and severity of
infections, thereby reducing morbidity and potentially mortality.
Comparison: The investigators are conducting a randomized clinical trial of IVIG versus
placebo for lung transplant patients with severe HGG to see if IVIG decreases the number of
bacterial infections in these patients.
- Lung transplant recipients >3 months after transplant surgery
- IgG < 500 mg/dL
- Stable medical regimen
- Acute rejection
- Active infection
- Contraindication to IVIG
- Recent thrombotic event